Price
Financials
Consolidated, Rs crore| Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 363 | 403 | 390 | 424 | 404 | 380 | 392 | 422 | 375 | 437 | 362 | 534 |
| Expenses | 287 | 316 | 316 | 348 | 298 | 286 | 280 | 318 | 273 | 321 | 267 | 388 |
| Operating Profit | 75 | 88 | 74 | 76 | 106 | 94 | 112 | 105 | 102 | 116 | 95 | 146 |
| OPM % | 21% | 22% | 19% | 18% | 26% | 25% | 29% | 25% | 27% | 27% | 26% | 27% |
| Other Income | 4 | 1 | 8 | 73 | 4 | 8 | -1 | 13 | 7 | 8 | 16 | 4 |
| Interest | 21 | 18 | 26 | 25 | 32 | 26 | 18 | 20 | 22 | 19 | 13 | 10 |
| Depreciation | 31 | 24 | 25 | 71 | 26 | 34 | 31 | 30 | 28 | 31 | 51 | 57 |
| Profit before tax | 29 | 47 | 31 | 53 | 52 | 42 | 62 | 67 | 58 | 74 | 46 | 83 |
| Tax % | 17% | 29% | 21% | 27% | 23% | 34% | 27% | 26% | 22% | 26% | 37% | 48% |
| Net Profit | 24 | 33 | 24 | 39 | 40 | 28 | 44 | 50 | 46 | 55 | 29 | 43 |
| EPS in Rs | 2.95 | 4.13 | 2.98 | 4.78 | 4.96 | 3.44 | 5.55 | 6.19 | 2.82 | 3.39 | 1.79 | 2.65 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 277 | 578 | 803 | 1,062 | 915 | 1,031 | 1,124 | 1,272 | 1,385 | 1,589 | 1,596 | 1,708 |
| Expenses | 213 | 468 | 659 | 801 | 712 | 830 | 899 | 982 | 1,053 | 1,275 | 1,186 | 1,249 |
| Operating Profit | 65 | 110 | 144 | 261 | 203 | 202 | 225 | 290 | 332 | 314 | 410 | 460 |
| OPM % | 23% | 19% | 18% | 25% | 22% | 20% | 20% | 23% | 24% | 20% | 26% | 27% |
| Other Income | 12 | 31 | 60 | 8 | 29 | 14 | 13 | 18 | 25 | 86 | 27 | 34 |
| Interest | 10 | 19 | 34 | 49 | 39 | 56 | 73 | 79 | 92 | 90 | 94 | 65 |
| Depreciation | 12 | 26 | 47 | 63 | 59 | 69 | 77 | 84 | 109 | 151 | 109 | 168 |
| Profit before tax | 55 | 96 | 123 | 157 | 134 | 91 | 88 | 145 | 156 | 159 | 233 | 261 |
| Tax % | 6% | 4% | 2% | 7% | 13% | 12% | 35% | 31% | 30% | 25% | 27% | |
| Net Profit | 51 | 92 | 120 | 146 | 117 | 80 | 57 | 100 | 109 | 120 | 171 | 172 |
| EPS in Rs | 12.70 | 15.02 | 18.12 | 14.55 | 9.91 | 7.03 | 12.43 | 13.54 | 14.85 | 21.20 | 10.65 | |
| Dividend Payout % | 9% | 8% | 7% | 7% | 8% | 12% | 17% | 10% | 9% | 13% | 9% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 19% | 9% | 8% | 7% | ||
| Compounded Profit Growth | 13% | 16% | 20% | 6% | ||
| Stock Price CAGR | 2% | % | % | % | ||
| Return on Equity | 13% | 10% | 11% | 13% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 14 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 175 | 301 | 558 | 688 | 768 | 863 | 915 | 1,018 | 1,165 | 1,222 | 1,435 |
| Borrowings | 325 | 561 | 630 | 724 | 774 | 868 | 850 | 854 | 974 | 933 | 943 |
| Other Liabilities | 82 | 285 | 262 | 224 | 232 | 334 | 469 | 403 | 472 | 638 | 586 |
| Total Liabilities | 596 | 1,161 | 1,466 | 1,652 | 1,790 | 2,081 | 2,249 | 2,291 | 2,628 | 2,809 | 2,981 |
| Fixed Assets | 175 | 538 | 685 | 778 | 843 | 1,012 | 1,033 | 1,373 | 1,505 | 1,441 | 1,545 |
| CWIP | 37 | 65 | 148 | 223 | 357 | 307 | 418 | 97 | 79 | 142 | 85 |
| Investments | 7 | 14 | 1 | 1 | 1 | 1 | 26 | 25 | 25 | 25 | 25 |
| Other Assets | 376 | 544 | 631 | 650 | 588 | 761 | 771 | 796 | 1,019 | 1,201 | 1,325 |
| Total Assets | 596 | 1,161 | 1,466 | 1,652 | 1,790 | 2,081 | 2,249 | 2,291 | 2,628 | 2,809 | 2,981 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 15 | 43 | 49 | 132 | 302 | 203 | 154 | 165 | 344 | 294 | 279 |
| Cash from Investing Activity | -82 | -418 | -252 | -168 | -295 | -231 | -104 | -117 | -257 | -158 | -153 |
| Cash from Financing Activity | 192 | 275 | 205 | 44 | -7 | 25 | -68 | -50 | -74 | -142 | -94 |
| Net Cash Flow | 126 | -100 | 2 | 8 | 0 | -3 | -18 | -2 | 14 | -6 | 32 |
| Free Cash Flow | -68 | -373 | -220 | -37 | -2 | -37 | 59 | 31 | 56 | 156 | 158 |
| CFO/OP | 29% | 44% | 41% | 56% | 157% | 107% | 74% | 63% | 113% | 108% | 82% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 114 | 79 | 80 | 51 | 45 | 60 | 61 | 21 | 38 | 50 | 35 |
| Inventory Days | 306 | 537 | 375 | 339 | 316 | 272 | 253 | 328 | 414 | 298 | 524 |
| Days Payable | 134 | 118 | 74 | 55 | 104 | 172 | 157 | 102 | 82 | 101 | 94 |
| Cash Conversion Cycle | 286 | 498 | 381 | 335 | 258 | 160 | 157 | 247 | 369 | 247 | 465 |
| Working Capital Days | 208 | 151 | 157 | 138 | 137 | 98 | 92 | 103 | 118 | 109 | 140 |
| ROCE % | 16% | 14% | 16% | 12% | 9% | 9% | 12% | 12% | 12% | 14% |
| Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | |
|---|---|---|---|---|
| Promoters | 61.40% | 61.40% | 61.40% | 61.40% |
| FIIs | 19.30% | 15.75% | 15.08% | 10.92% |
| DIIs | 4.64% | 7.26% | 7.87% | 9.92% |
| Public | 14.66% | 15.59% | 15.65% | 17.76% |
| No. of Shareholders | 47,781 | 43,899 | 52,291 | 52,417 |
Fundamentals
Market Cap₹ 4,861 Cr.
Current Price₹ 301
Stock P/E28.3
Book Value₹ 104
ROCE14.3 %
ROE12.6 %
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)7%
Compounded Profit Growth (TTM)6%
Consolidated figures.
Valuation
Market capRs 4,861 Cr
Enterprise valueRs 5,742 Cr
P/E (TTM)28.27x
Price to book3.35x
Price to sales2.85x
EV / EBITDA11.63x
EV / EBIT17.62x
EV / sales3.36x
Price to cash flow17.45x
Earnings yield3.54%
Dividend yield0.33%
P/E, 3-year average11.08x
P/B, 3-year average1.17x
P/E, 5-year average9.06x
P/B, 5-year average0.89x
Profitability
Operating margin (excl. other income)25.71%
Operating margin (incl. other income)27.37%
EBITDA margin28.89%
Pre-tax margin15.27%
Net profit margin10.06%
Net margin, latest quarter8.01%
ROE12.73%
ROCE14.36%
ROA5.91%
ROE, 3-year average10.83%
ROCE, 3-year average12.72%
ROA, 3-year average4.92%
ROE, 5-year average9.79%
ROCE, 5-year average11.90%
ROA, 5-year average4.36%
ROIC (approx.)10.24%
Tax rate26.72%
Other income / net worth1.83%
Growth
Sales growth (latest year)0.46%
Profit growth (latest year)42.82%
Sales CAGR, 3 years7.85%
Sales CAGR, 5 years9.13%
Profit CAGR, 3 years19.49%
Profit CAGR, 5 years16.42%
Sales growth QoQ47.55%
Profit growth QoQ47.76%
Sales growth YoY (latest quarter)26.56%
Profit growth YoY (latest quarter)-14.28%
Per share
EPS (TTM)Rs 10.65
EPS (latest year)Rs 21.20
EPS (latest quarter)Rs 2.65
EPS, 3-year averageRs 16.53
EPS, 5-year averageRs 13.81
Book value per shareRs 89.94
Sales per shareRs 105.84
Cash flow per shareRs 17.26
Free cash flow per shareRs 9.79
Dividend per share (latest year)Rs 2.00
Dividend per share, 3-year averageRs 1.73
Dividend per share, 5-year averageRs 1.52
Dividends
Dividend payout9.43%
Dividend payout, 3-year average10.59%
Dividend payout, 5-year average11.69%
Efficiency
Asset turnover0.54x
Fixed asset turnover1.03x
Inventory turnover0.99x
Inventory days369 days
Debtor days35 days
Debtors turnover10.48x
Creditor days94 days
Cash conversion cycle465 days
Working capital days140 days
Leverage
Total debtRs 943 Cr
Cash and bankRs 62 Cr
Net debtRs 881 Cr
Debt to equity0.65x
Net debt / EBITDA1.78x
Interest coverage5.02x
Owners' fund to total sources48.70%
Debt to assets31.63%
Cash flow
Cash from Operating Activity (latest year)Rs 279 Cr
Cash from Investing Activity (latest year)Rs -153 Cr
Cash from Financing Activity (latest year)Rs -94 Cr
Net Cash Flow (latest year)Rs 32 Cr
Free cash flow (latest year)Rs 158 Cr
FCFE (approx.: FCF + change in debt)Rs 168 Cr
Cash from ops / profit, 5 years2.22x
Sales to cash flow5.73x
Statement figures
Net sales (TTM)Rs 1,708 Cr
Net sales (latest year)Rs 1,596 Cr
Sales (latest quarter)Rs 534 Cr
Operating profit excl. other income (latest year)Rs 410 Cr
Operating profit (latest quarter)Rs 146 Cr
Other income (TTM)Rs 34 Cr
EBITDA (TTM)Rs 494 Cr
PBDT (TTM)Rs 429 Cr
Profit before tax (TTM)Rs 261 Cr
Tax (latest year)Rs 62 Cr
Net profit (TTM)Rs 172 Cr
Net profit (latest year)Rs 171 Cr
Net profit (latest quarter)Rs 43 Cr
Depreciation (TTM)Rs 168 Cr
Depreciation (latest quarter)Rs 57 Cr
Interest (TTM)Rs 65 Cr
Cost of goods sold (latest year)Rs 478 Cr
Total expenditure (latest year)Rs 1,186 Cr
Total income (latest year)Rs 1,623 Cr
Share capitalRs 16 Cr
ReservesRs 1,435 Cr
Shareholders' fundsRs 1,452 Cr
Total assetsRs 2,981 Cr
Net blockRs 1,545 Cr
Capital work in progressRs 85 Cr
InvestmentsRs 25 Cr
ReceivablesRs 152 Cr
InventoryRs 483 Cr
Other liabilitiesRs 586 Cr
Shares outstanding (crore)16.14
Ownership
Promoter holding61.40%
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | DISHMAN | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +3.4% | -2.8% | +6.2 pts |
| 1 month | -4.4% | -6.8% | +2.4 pts |
| 3 months | +31.6% | -7.6% | +39.3 pts |
| 6 months | +25.8% | +0.4% | +25.4 pts |
| 1 year | +94.2% | -9.9% | +104.1 pts |
| 2 years | +297.1% | -13.6% | +310.7 pts |
| 3 years | +577.2% | +14.2% | +563.0 pts |
| 5 years | +1023.9% | +27.9% | +996.0 pts |
Red flags
F-score 7 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2017Sales ₹534 Cr +26.5% vs Mar 2016.
Net profit ₹43 Cr -14.0%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2017-02-17 | Interim Dividend Rs 1.20 Per Share (Purpose Revised) | |
| 2016-09-16 | Annual General Meeting | |
| 2016-05-02 | Bonus 1:1 | 0.5000 |
| 2016-03-17 | Interim Dividend - Rs 2/- Per Share (Purpose Revised) | |
| 2015-09-10 | Annual General Meeting/Dividend - Rs 2/- Per Share | |
| 2014-08-21 | Annual General Meeting / Final Dividend - Rs 1.20/- Per Share | |
| 2013-07-18 | Annual General Meeting And Dividend Rs.1.20 Per Share | |
| 2012-09-13 | Annual General Meeting/Dividend Rs.1.20 Per Share | |
| 2011-07-14 | Annual General Meeting And Dividend Rs.1.20 Per Share | |
| 2010-07-15 | Annual General Meeting And Dividend Rs.1.20 Per Share | |
| 2009-07-14 | Agm/Div-Rs.1.20 Per Share | |
| 2008-07-17 | Agm/Dividend-50% | |
| 2007-07-26 | Agm/Dividend-50% | |
| 2006-06-21 | Agm/Final Dividend-35% |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Dishman Pharmaceuticals and Chemicals Ltd(Merged)?
Dishman Pharmaceuticals and Chemicals Ltd(Merged) (DISHMAN) has a market capitalisation of Rs 4,861 Cr. at the 2017-05-29 close.
What is the P/E ratio of Dishman Pharmaceuticals and Chemicals Ltd(Merged)?
Dishman Pharmaceuticals and Chemicals Ltd(Merged) trades at a P/E of 28.3 on trailing twelve-month profit, at the 2017-05-29 close.
What were Dishman Pharmaceuticals and Chemicals Ltd(Merged)'s latest quarterly results?
In the Mar 2017 quarter, Dishman Pharmaceuticals and Chemicals Ltd(Merged) sales was Rs 534 Cr (+26.5% vs Mar 2016) and net profit was Rs 43 Cr.